Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
2021 · Journal of the American College of Cardiology · 131 citations
https://doi.org/10.1016/j.jacc.2021.04.102
H
Héctor Luciardi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
65
Papers
3.1K
Citations
20
h-index
25
i10-index
Héctor Luciardi is an academic researcher. The author has contributed to research in topics: Atrial Fibrillation Management and Outcomes & Trypanosoma species research and implications & Antiplatelet Therapy and Cardiovascular Diseases. The author has an h-index of 20, co-authored 56 publications.
Papers by this author
worksThe antithrombotic profile of aspirin. Aspirin resistance, or simply failure?
2004 · Thrombosis Journal · 114 citations
https://doi.org/10.1186/1477-9560-2-1
RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial
2021 · EClinicalMedicine · 52 citations
https://doi.org/10.1016/j.eclinm.2021.100843
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
2025 · Circulation · 19 citations
https://doi.org/10.1161/circulationaha.124.071269
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat